STRIDES PHARMA NEWS
JioBlackRock Flexi Cap Fund exits NALCO, Hindustan Zinc; trims exposure in BSE, RIL
JioBlackRock Flexi Cap Fund reshuffled its portfolio in August, exiting 21 stocks while reducing exposure to 34 others, including NALCO, Hindustan Zinc and RIL. It increased holdings in 17 stocks and added 22 new names. The fund’s portfolio grew to 136 stocks, with banks accounting for its largest sector allocation.
Strides Pharma Science shares jump 9% after USFDA EIR for Bengaluru facility
Strides Pharma Science shares rise sharply on Thursday after the USFDA issued an Establishment Inspection Report (EIR) for its Bengaluru facility, concluding a recent cGMP inspection. The inspection ended with five observations, which the company addressed through corrective actions. The regulatory closure offers relief after the stock’s recent weakness.
Stock Radar: Strides Pharma breaks out from 7-month consolidation to hit fresh 52-week high; time to buy?
Strides Pharma Science stock shows positive movement. It broke a seven-month consolidation phase. Experts suggest a buy with a target of Rs 960 in 1-2 months. The stock demonstrated strong momentum, breaking resistance at Rs 760. Technical indicators support a bullish outlook. A stop loss is advised at Rs 750 for risk management. Market participation has increased.
Stock Radar: This pharma stock sees mild consolidation after 130% rally in 1 year; time to buy the dip?
The pharma stock is a part of the S&P BSE Smallcap index. It saw an uptrend, rising from Rs 393 as of June 9, 2023, to Rs 901 recorded on June 10, 2024. It has, however, undergone mild consolidation of approximately 100 points since April on the daily chart. The stock is in recovery mode with chances of momentum to continue are moderate. Short-term traders can look to accumulate the stock on dips.
Buy Strides Pharma Science, target price Rs 630: Prabhudas Lilladher
Promoters held 28.07 per cent stake in the company as of 30-Jun-2023, while FIIs owned 16.72 per cent, DIIs 19.59 per cent.
- Go To Page 1
Reduce Strides Pharma Science, target price Rs 495: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 4766.18 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 500: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3085.64 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 402: ICICI Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 3026.83 Crore) operating in Pharmaceuticals sector.
Accumulate Strides Pharma Science, target price Rs 355: Geojit
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2836.92 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 355: Edelweiss
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2914.80 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 337: Yes Securities
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 2854.19 Crore) operating in Pharmaceuticals sector.
Buy Strides Pharma Science, target price Rs 930: Motilal Oswal
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 7243.98 Crore) operating in Pharmaceuticals sector.
Strides Pharma to conduct trials in India for potential COVID-19 drug
The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details.
Sell Strides Pharma Science, target Rs 386: Kunal Bothra
Sell Strides Pharma Science Ltd. at a price target of Rs 386.0 and a stoploss at Rs 405 from entry point.
Sell Strides Pharma Science, target Rs 360: CA Rudramurthy
Sell Strides Pharma Science Ltd. at a price target of Rs 360.0 and a stoploss at Rs 390 from entry point.
Sell Strides Pharma, target Rs 375: Manas Jaiswal
Sell Strides Pharma at a price target of Rs 375 and a stoploss at Rs 406.
Sell Strides Pharma Science, target Rs 400: Kunal Bothra
Sell Strides Pharma Science Ltd. at a price target of Rs 400.0 and a stoploss at Rs 420 from entry point.
USFDA recommends action against Strides Pharma Science Puducherry unit
The company believes that the classification will not have an impact on the current supplies and revenues from the facility," Strides Pharma said.
Strides Pharma drops 3% on USFDA observation for Bengaluru plant
The observations are not material in nature, the company said.
MCX, Sun Pharma, PNB Housing and Strides Pharma among stocks in the news
Here's a look at the top stocks that may hog the limelight in today's session.
Pharma looks best export theme, valuations attractive: Deepak Shenoy
FDA plant warnings have increased of late; Trans-Pacific Partnership has reduced pharma companies' access to some pacific countries, says Shenoy.
Smaller names in pharma space may have good strides: Prakash Diwan
"There is lot of news flow driven moves that you continuously see in this space"
Strides Arcolab set to acquire Shasun Pharma in an all-stock deal
Shareholders of Chennai-based Shasun Pharma will receive five equity shares of Strides for every 16 equity shares they hold in the company.
Mainstay gone, strides in for a rough ride
The company had earlier acquired assets, improved efficiencies and subsequently sold them at attractive valuations.
Strides Arcolabs' Agila Specialties Pharma Corporation forms JV with Jamp Pharma
Strides Arcolabs' injectable drug division Agila Specialties Pharma Corporation has formed a 70:30 JV with Jamp Pharma to introduce injectable generic drugs in Canada.
Buy Strides Arcolab from a long term perspective: Sonam Udasi
"If you have a long term, go for stocks like Strides Arcolab even Aurobindo Pharma after that huge correction we saw."
Accumulate Strides Arcolab on every dip: Ashit Suri
Ashit Suri, Fundamental Research Analyst, JV Capital Services in an interview with ET Now talks about his pick from the pharma stocks.
Load More
